IPO - KalVista Pharmaceuticals, Inc.

Form Type: 424B5

Filing Date: 2025-07-10

Corporate Action: Ipo

Type: New

Accession Number: 000119312525157622

Filing Summary: KalVista Pharmaceuticals, Inc. has filed a prospectus supplement relating to an offering of up to $100,000,000 of its common stock. The company has entered into a sales agreement with TD Cowen, who will act as an agent for the offering. Shares will be sold 'at the market' at prices based on the prevailing market conditions. The most recent reported sales price was $15.99 per share. TD Cowen does not guarantee any specific number of shares to be sold but will use commercially reasonable efforts to act in accordance with the agreement. The net proceeds from the offering will primarily be used for general corporate purposes and specifically for the commercialization of EKTERLY, a newly FDA-approved drug for treating hereditary angioedema. The prospectus further indicates that the company adheres to reduced reporting requirements under federal securities laws as a smaller reporting company and provides various disclaimers regarding investment risks associated with the offering.